BridgeBio Pharma advertising spend, FY2025

BridgeBio Pharma (BBIO) reported $110M of advertising expense for the fiscal year ended Dec 31, 2025. That is 21.9% of revenue of $502M. Up 412.1% from FY2024.

Ad spend, FY2025
$110M
year ended Dec 31, 2025
Change vs prior year
+412.1%
vs FY2024
Share of revenue
21.9%
of $502M revenue
Rank by ad spend
#320
of 458 companies

Key facts

  • Ad spend is 5.1x its FY2024 level ($21.5M), faster than revenue (2.3x).
  • BridgeBio Pharma spends more on advertising than 30% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is 4.8x the median of 4.5%.

Ad spend by fiscal year

$0 $50M $100M $150M FY2023 (ended 2023-12-31): $0 2023 FY2024 (ended 2024-12-31): $21.5M 2024 FY2025 (ended 2025-12-31): $110M 2025 $110M

Ad spend as % of revenue

0% 10% 20% 30% FY2023 (ended 2023-12-31): 0.0% 2023 FY2024 (ended 2024-12-31): 9.7% 2024 FY2025 (ended 2025-12-31): 21.9% 2025 21.9%

Ad spend in context, FY2025

Advertising was 20.7% of selling, general and administrative expense. Research and development spending was 4.1x advertising. The company reported an operating loss of $523M.

Advertising $110M AdvertisingExpense
Selling, general and administrative $531M ad spend = 20.7%
Research and development $452M R&D = 4.1x ad spend
Operating loss -$523M

Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.

History

Download CSV
Fiscal year Period end Ad spend YoY Revenue Ad / revenue Tag Filing
FY2025 Dec 31, 2025 $110M +412.1% $502M 21.9% AdvertisingExpense 10-K Feb 24, 2026
FY2024 Dec 31, 2024 $21.5M n/a $222M 9.7% AdvertisingExpense 10-K Feb 24, 2026
FY2023 Dec 31, 2023 $0 n/a $9.3M 0.0% AdvertisingExpense 10-K Feb 24, 2026

Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank. A $0 value is what the filing tagged for that year.

What the figure is

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Compared with similar spenders

The 6 companies closest to BridgeBio Pharma in latest-year ad spend.

Rank Company Ad spend Ad / revenue YoY Fiscal year
319 Lucid Group $112M 8.3% +125.3% FY2025
320 BridgeBio Pharma $110M 21.9% +412.1% FY2025
321 Cars.com $109M 15.1% +3.6% FY2025
322 Versant Media Group $109M 1.6% +32.9% FY2025
323 D.R. Horton $108M 0.3% +49.7% FY2025
324 Corpay $108M 2.4% +43.6% FY2025
325 Tractor Supply $108M 0.7% +13.1% FY2025

Full ranking of 458 companies · Biggest increases #2 · Highest ad-to-revenue #37 · New $50M spenders #3 · Ads above operating profit #113

Questions

How much does BridgeBio Pharma spend on advertising?

BridgeBio Pharma spent $110M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 24, 2026.

What percentage of revenue does BridgeBio Pharma spend on advertising?

21.9% of revenue in fiscal 2025 ($110M against $502M). The median across the 458 companies tracked is 4.5%.

Is BridgeBio Pharma spending more on advertising?

Yes. Ad spend rose 412.1% in fiscal 2025 from fiscal 2024.

How does BridgeBio Pharma rank by advertising spend?

#320 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.

Does BridgeBio Pharma spend more on advertising than on R&D?

No. In fiscal 2025 it spent $452M on research and development and $110M on advertising.

What does BridgeBio Pharma's advertising figure include?

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Company and source

Filing
10-K for FY2025, filed Feb 24, 2026
Accession number
0001743881-26-000009
Company
BridgeBio Pharma, Inc., CIK 1743881, SIC 2834 (Pharmaceutical Preparations)
Headquarters
Palo Alto, CA
Incorporated in
DE
Fiscal year ends
December 31
Listed on
Nasdaq
SEC filer status
Large accelerated filer
Data
SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
Cite
BridgeBio Pharma advertising spend, FY2023-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 24, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/bridgebio-pharma/advertising-spend/
Download
CSV, all years · CSV, all 458 companies